Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT05519059
- Locations
- 🇨🇳
Bethune First Hospital of Jilin University, Chang chun, Jilin, China
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05191667
- Locations
- 🇨🇳
Jianming Xu, Beijing, Beijing, China
First in Human, Dose Escalation Study of AN4005
- Conditions
- Advanced LymphomaAdvanced Solid Tumor
- Interventions
- Drug: AN4005-dose level 3Drug: AN4005-dose level 0Drug: AN4005-dose level 1Drug: AN4005-dose level 2Drug: AN4005-food effectDrug: AN4005-dose level 4
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT04999384
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Montefiore Einstein Cancer Center, Bronx, New York, United States
🇺🇸Prisma Health Institute for Translational Oncology Research, Greenville, South Carolina, United States
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
- Conditions
- Locally Advanced Solid Tumor
- Interventions
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT04975958
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Florida Cancer Specialists - Lake Mary Cancer Center, Lake Mary, Florida, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
- Conditions
- NSCLC, Squamous or Non-SquamousTriple-negative Breast CancerMicrosatellite Stable (MSS) Colorectal Cancer (CRC)Cervical CancerUrothelial Carcinoma of the Bladder
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT04432857
- Locations
- 🇺🇸
Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Utah School of Medicine Huntsman Cancer Institute, Salt Lake City, Utah, United States
- Prev
- 1
- 2
- Next